The biotech sector has been bifurcated of lateThe large cap names are holding up well while scores of small cap names have fallen back 10% to 20% over the past few weeks on little new company specific newsLast week was a perfect example of this recent trading actionAmgen (AMGN) , Celgene (CELG) and Allergan (AGN) all rose approximately 3%, while ...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.